Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fexuprazan + aspirin (Daewoong Pharmaceutical)
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
F2B22E + DL001Z is a fixed-dose combination (FDC) product developed by Daewoong Pharmaceutical, consisting of fexuprazan (a potassium-competitive acid blocker, P-CAB) and aspirin (an antiplatelet agent). The combination is specifically designed for patients who require long-term aspirin therapy for the prevention of cardiovascular and cerebrovascular events but are at high risk of developing aspirin-induced gastric or duodenal ulcers. Fexuprazan provides rapid and potent inhibition of gastric acid secretion by reversibly binding to the H+/K+-ATPase pump in parietal cells, thereby protecting the gastric mucosa from the erosive effects of aspirin, which inhibits protective prostaglandin synthesis. This FDC aims to improve patient compliance and safety in chronic antiplatelet management.
- Other names
- fexuprazan hydrochloride + aspirinDWJ1553DWJ-1553DWJ 1553
02
Targets
ATP4A (Potassium–transporting ATPase alpha chain 1)PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on fexuprazan + aspirin (Daewoong Pharmaceutical).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fexuprazan + aspirin (Daewoong Pharmaceutical).